382 related articles for article (PubMed ID: 25182153)
1. L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer.
Shim EH; Livi CB; Rakheja D; Tan J; Benson D; Parekh V; Kho EY; Ghosh AP; Kirkman R; Velu S; Dutta S; Chenna B; Rea SL; Mishur RJ; Li Q; Johnson-Pais TL; Guo L; Bae S; Wei S; Block K; Sudarshan S
Cancer Discov; 2014 Nov; 4(11):1290-8. PubMed ID: 25182153
[TBL] [Abstract][Full Text] [Related]
2. Teleological role of L-2-hydroxyglutarate dehydrogenase in the kidney.
Brinkley G; Nam H; Shim E; Kirkman R; Kundu A; Karki S; Heidarian Y; Tennessen JM; Liu J; Locasale JW; Guo T; Wei S; Gordetsky J; Johnson-Pais TL; Absher D; Rakheja D; Challa AK; Sudarshan S
Dis Model Mech; 2020 Nov; 13(11):. PubMed ID: 32928875
[TBL] [Abstract][Full Text] [Related]
3. Renal oncometabolite L-2-hydroxyglutarate imposes a block in kidney tubulogenesis: Evidence for an epigenetic basis for the L-2HG-induced impairment of differentiation.
Taub M; Mahmoudzadeh NH; Tennessen JM; Sudarshan S
Front Endocrinol (Lausanne); 2022; 13():932286. PubMed ID: 36133305
[TBL] [Abstract][Full Text] [Related]
4. Oncometabolite L-2-hydroxyglurate directly induces vasculogenic mimicry through PHLDB2 in renal cell carcinoma.
Wang H; Wang L; Zheng Q; Lu Z; Chen Y; Shen D; Xue D; Jiang M; Ding L; Zhang J; Wu H; Xia L; Qian J; Li G; Lu J
Int J Cancer; 2021 Apr; 148(7):1743-1755. PubMed ID: 33320958
[TBL] [Abstract][Full Text] [Related]
5. Another small molecule in the oncometabolite mix: L-2-Hydroxyglutarate in kidney cancer.
Shim EH; Sudarshan S
Oncoscience; 2015; 2(5):483-6. PubMed ID: 26097881
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer.
Shelar S; Shim EH; Brinkley GJ; Kundu A; Carobbio F; Poston T; Tan J; Parekh V; Benson D; Crossman DK; Buckhaults PJ; Rakheja D; Kirkman R; Sato Y; Ogawa S; Dutta S; Velu SE; Emberley E; Pan A; Chen J; Huang T; Absher D; Becker A; Kunick C; Sudarshan S
Clin Cancer Res; 2018 Dec; 24(24):6433-6446. PubMed ID: 30108105
[TBL] [Abstract][Full Text] [Related]
7. Quantitative Analysis of Oncometabolite 2-Hydroxyglutarate.
Yuan BF
Adv Exp Med Biol; 2021; 1280():161-172. PubMed ID: 33791981
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia Induces Production of L-2-Hydroxyglutarate.
Intlekofer AM; Dematteo RG; Venneti S; Finley LW; Lu C; Judkins AR; Rustenburg AS; Grinaway PB; Chodera JD; Cross JR; Thompson CB
Cell Metab; 2015 Aug; 22(2):304-11. PubMed ID: 26212717
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma.
Miyake K; Baba Y; Ishimoto T; Hiyoshi Y; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Ogata Y; Nagayama M; Silsirivanit A; Kobayashi D; Araki N; Baba H
Med Oncol; 2018 Nov; 36(1):11. PubMed ID: 30506321
[TBL] [Abstract][Full Text] [Related]
10. Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells.
Smolková K; Dvořák A; Zelenka J; Vítek L; Ježek P
Int J Biochem Cell Biol; 2015 Aug; 65():125-33. PubMed ID: 26007236
[TBL] [Abstract][Full Text] [Related]
11. A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor.
Elhammali A; Ippolito JE; Collins L; Crowley J; Marasa J; Piwnica-Worms D
Cancer Discov; 2014 Jul; 4(7):828-39. PubMed ID: 24740997
[TBL] [Abstract][Full Text] [Related]
12. Oncometabolite d-2HG alters T cell metabolism to impair CD8
Notarangelo G; Spinelli JB; Perez EM; Baker GJ; Kurmi K; Elia I; Stopka SA; Baquer G; Lin JR; Golby AJ; Joshi S; Baron HF; Drijvers JM; Georgiev P; Ringel AE; Zaganjor E; McBrayer SK; Sorger PK; Sharpe AH; Wucherpfennig KW; Santagata S; Agar NYR; Suvà ML; Haigis MC
Science; 2022 Sep; 377(6614):1519-1529. PubMed ID: 36173860
[TBL] [Abstract][Full Text] [Related]
13. Drosophila larvae synthesize the putative oncometabolite L-2-hydroxyglutarate during normal developmental growth.
Li H; Chawla G; Hurlburt AJ; Sterrett MC; Zaslaver O; Cox J; Karty JA; Rosebrock AP; Caudy AA; Tennessen JM
Proc Natl Acad Sci U S A; 2017 Feb; 114(6):1353-1358. PubMed ID: 28115720
[TBL] [Abstract][Full Text] [Related]
14. 2-Hydroxyglutarate in Cancer Cells.
Ježek P
Antioxid Redox Signal; 2020 Nov; 33(13):903-926. PubMed ID: 31847543
[No Abstract] [Full Text] [Related]
15. Oncometabolite D-2-Hydroxyglurate Directly Induces Epithelial-Mesenchymal Transition and is Associated with Distant Metastasis in Colorectal Cancer.
Colvin H; Nishida N; Konno M; Haraguchi N; Takahashi H; Nishimura J; Hata T; Kawamoto K; Asai A; Tsunekuni K; Koseki J; Mizushima T; Satoh T; Doki Y; Mori M; Ishii H
Sci Rep; 2016 Nov; 6():36289. PubMed ID: 27824159
[TBL] [Abstract][Full Text] [Related]
16. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A
Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619
[TBL] [Abstract][Full Text] [Related]
17. Sensitive Determination of Onco-metabolites of D- and L-2-hydroxyglutarate Enantiomers by Chiral Derivatization Combined with Liquid Chromatography/Mass Spectrometry Analysis.
Cheng QY; Xiong J; Huang W; Ma Q; Ci W; Feng YQ; Yuan BF
Sci Rep; 2015 Oct; 5():15217. PubMed ID: 26458332
[TBL] [Abstract][Full Text] [Related]
18. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.
Losman JA; Looper RE; Koivunen P; Lee S; Schneider RK; McMahon C; Cowley GS; Root DE; Ebert BL; Kaelin WG
Science; 2013 Mar; 339(6127):1621-5. PubMed ID: 23393090
[TBL] [Abstract][Full Text] [Related]
19. Loss of 5-hydroxymethylcytosine is linked to gene body hypermethylation in kidney cancer.
Chen K; Zhang J; Guo Z; Ma Q; Xu Z; Zhou Y; Xu Z; Li Z; Liu Y; Ye X; Li X; Yuan B; Ke Y; He C; Zhou L; Liu J; Ci W
Cell Res; 2016 Jan; 26(1):103-18. PubMed ID: 26680004
[TBL] [Abstract][Full Text] [Related]
20. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives.
Mondesir J; Willekens C; Touat M; de Botton S
J Blood Med; 2016; 7():171-80. PubMed ID: 27621679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
